Henrik Stenqvist
Directeur Financier/CFO chez SWEDISH ORPHAN BIOVITRUM AB
Fortune : 2 M $ au 30/04/2024
Profil
Henrik Stenqvist is currently an Independent Non-Executive Director at Calliditas Therapeutics AB, a Director at Dova Pharmaceuticals, Inc., and a Co-Managing Director at Swedish Orphan Biovitrum GmbH.
He is also a Director at Swedish Orphan Biovitrum, Inc., Swedish Orphan Biovitrum Ltd., and Orion Oyj, starting in 2024.
In 2018, Mr. Stenqvist served as the Chief Financial Officer at Swedish Orphan Biovitrum AB.
In his former positions, Mr. Stenqvist worked as a Regional Finance Director at AstraZeneca AB, an Independent Director at MedCap AB, and a Finance Director at Astra Export & Trading AB.
From 2017 to 2024, he was an Independent Director at Midsona AB.
Mr. Stenqvist also held positions such as Treasurer at CTI BioPharma Corp., Chief Financial Officer & Executive Vice President at Meda AB, Chief Financial Officer & Executive Vice President at Recipharm AB, and Chief Financial Officer at MEDA Manufacturing GmbH.
He was also a Chief Financial Officer at Calliditas Therapeutics AB.
Mr. Stenqvist completed his undergraduate and MBA degrees at the University of Linköping.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/10/2023 | 51 620 ( 0,01% ) | 1 M $ | 30/04/2024 | |
| 29/02/2024 | 10 000 ( 0,02% ) | 100 220 $ | 30/04/2024 | |
MIDSONA AB CLASS B
0,08% | 28/02/2023 | 120 000 ( 0,08% ) | 87 901 $ | 30/04/2024 |
Postes actifs de Henrik Stenqvist
| Sociétés | Poste | Début |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Directeur Financier/CFO | 20/07/2018 |
| DOVA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 12/11/2019 |
| CALLIDITAS THERAPEUTICS AB | Directeur/Membre du Conseil | 01/01/2022 |
| ORION OYJ | Directeur/Membre du Conseil | 20/03/2024 |
Swedish Orphan Biovitrum Ltd.
 Swedish Orphan Biovitrum Ltd. Pharmaceuticals: MajorHealth Technology Part of Swedish Orphan Biovitrum AB, Swedish Orphan Biovitrum Ltd. manufactures and sells drugs for rare diseases. The company is based in Cambridge, UK and was founded in 2002. | Directeur/Membre du Conseil | 20/07/2018 |
Swedish Orphan Biovitrum GmbH
 Swedish Orphan Biovitrum GmbH Miscellaneous Commercial ServicesCommercial Services Part of Swedish Orphan Biovitrum AB, Swedish Orphan Biovitrum GmbH engages in researching, developing, and innovating therapies that improve the lives of people with rare diseases. The company is based in Martinsried, Germany. The CEOs are Henrik Stenqvist, Thomas Trilling, Hege Hellstroem. The German company was founded in 2010. | Directeur Général | - |
Swedish Orphan Biovitrum, Inc.
 Swedish Orphan Biovitrum, Inc. Pharmaceuticals: MajorHealth Technology Swedish Orphan Biovitrum, Inc. operates as an international rare disease company providing access to treatments that make a significant difference for people with rare diseases. Its business areas include haemophilia, immunology and specialty care. The company is headquartered in Waltham, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Henrik Stenqvist
| Sociétés | Poste | Fin |
|---|---|---|
| MIDSONA AB | Directeur/Membre du Conseil | 07/05/2024 |
| RECIPHARM AB (PUBL) | Directeur Financier/CFO | - |
| ░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | - |
| ░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | - |
Formation de Henrik Stenqvist
| University of Linköping | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| MIDSONA AB | Health Technology |
| MEDCAP AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| CALLIDITAS THERAPEUTICS AB | Health Technology |
| ORION OYJ | Health Technology |
| Entreprise privées | 10 |
|---|---|
MEDA Manufacturing GmbH
 MEDA Manufacturing GmbH Pharmaceuticals: MajorHealth Technology MEDA Manufacturing GmbH manufactures and distributes pharmaceutical products. It offers product development, scale up, purchasing services, manufacturing, filling, packaging, final release and shipping. The company was founded on September 14, 1897 and is headquartered in Cologne, Germany. | Health Technology |
Meda AB
 Meda AB Pharmaceuticals: MajorHealth Technology Meda AB engages in the research, development, manufacture, and sale of pharmaceutical and medical products. It offers respiratory, dermatology, pain and inflammation, consumer healthcare, and over-the-counter products. The company was founded by Gert Lennart Perlhagen in 1999 and is headquartered in Solna, Sweden. | Health Technology |
Recipharm AB
 Recipharm AB BiotechnologyHealth Technology Recipharm AB engages in the manufacture of pharmaceuticals and contract development services for pharmaceutical companies. It operates through the following segments: Manufacturing Sterile and Inhalation (MFG-SI); Manufacturing Solids and Others (MFG-SO); Development and Technology (D&T); and Others and Eliminations. The MFG-SI segment includes manufacturing of products on behalf of pharmaceutical companies and covers sterile and inhalation technologies as well as liquid vials and ampoules, lyophilisates, blow-fill-seal products, and inhalation. The MFG-SO segment produces products on behalf of pharmaceutical companies and covers tablets, capsules, semi-solids, and non-sterile liquids. The D&T segment focuses on pharmaceutical development services. The company was founded by Lars Rickard Backsell and Thomas Bengt Eldered in 1995 and is headquartered in Stockholm, Sweden. | Health Technology |
Swedish Orphan Biovitrum, Inc.
Swedish Orphan Biovitrum, Inc. Pharmaceuticals: MajorHealth Technology Swedish Orphan Biovitrum, Inc. operates as an international rare disease company providing access to treatments that make a significant difference for people with rare diseases. Its business areas include haemophilia, immunology and specialty care. The company is headquartered in Waltham, MA. | Health Technology |
Swedish Orphan Biovitrum GmbH
Swedish Orphan Biovitrum GmbH Miscellaneous Commercial ServicesCommercial Services Part of Swedish Orphan Biovitrum AB, Swedish Orphan Biovitrum GmbH engages in researching, developing, and innovating therapies that improve the lives of people with rare diseases. The company is based in Martinsried, Germany. The CEOs are Henrik Stenqvist, Thomas Trilling, Hege Hellstroem. The German company was founded in 2010. | Commercial Services |
Swedish Orphan Biovitrum Ltd.
Swedish Orphan Biovitrum Ltd. Pharmaceuticals: MajorHealth Technology Part of Swedish Orphan Biovitrum AB, Swedish Orphan Biovitrum Ltd. manufactures and sells drugs for rare diseases. The company is based in Cambridge, UK and was founded in 2002. | Health Technology |
| Astra Export & Trading AB | |
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
